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Abstract
Objective—To determine the incidence rate and risk factors of tuberculosis (TB) among HIV-
infected adults accessing antiretroviral therapy (ART) in Tanzania.
Design—A prospective observational study among HIV-infected adults attending 47 HIV clinics 
in Dar es Salaam.
Methods—We estimated TB incidence rates among HIV-infected patients prior to and after ART 
initiation. We used Cox proportional hazard regressions to determine the predictors of incident TB 
among HIV-infected adults enrolled in the HIV care and treatment program.
Results—We assessed 67,686 patients for a median follow-up period of 24 (interquartile range: 
8–49) months; 7,602 patients were diagnosed with active TB. The TB incidence rate was 7.9 (95% 
Confidence Interval (CI), 7.6–8.2)/100 person-years prior to ART initiation, and 4.4(95%CI, 4.2–
4.4)/100 person-years for patients receiving ART. In multivariate analyses, patients on ART in the 
first 3 months had a 57% higher risk of TB (Hazard Ratio:1.57, 95%CI:1.47–1.68) compared to 
those not on ART, but the risk significantly decreased with increasing duration of ART. Risk 
factors for incident TB included being male, having low body mass index or middle upper arm 
circumference, lower CD4 cell count, and advanced WHO disease stage. There was seasonal 
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variation for incident TB, with higher risk observed following the rainy seasons (May, June, and 
November).
Conclusion—In TB endemic regions, HIV-infected patients initiating ART, particularly males 
and those with poor nutritional status, should be closely monitored for active TB in the months 
following ART initiation. In addition to increasing the access to ART, interventions should be 
considered to improve nutritional status among HIV-infected patients.
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Introduction
Tuberculosis (TB) continues to be a major public health threat globally as an estimated 9.0 
million new cases and 1.5 million TB deaths occurred worldwide in 2013[1]. World Health 
Organization (WHO) estimates that one third of the world’s population is infected with the 
latent form of TB and therefore at risk of progressing to active TB. For most individuals, the 
initial infection is contained by host defenses, and the infection remains latent. However 
among HIV-infected population, the risk of progression from latent TB to active TB is 
significantly higher. In 2013, globally people living with HIV are 29 times more likely to 
develop active TB disease than those who are HIV-negative[1]. It is also estimated that 1.1 
million (13%) of the 9.0 million people who developed TB worldwide in 2013 were HIV-
positive[1].
Approximately 25 million people are living with HIV/AIDS in sub-Saharan Africa[2]. The 
high HIV prevalence in this region has propagated a resurgence of both drug-susceptible and 
drug-resistant TB. According to a recent report by UNAIDS, over 75% of all estimated 
HIV-TB co-infected individuals live in just 10 countries, and nine of those countries are in 
sub-Saharan Africa[2]. The world has made substantial gains toward achieving the 
Millennium Development Goals (MDGs) of halving TB-related deaths among people living 
with HIV by 2015. From 2004 to 2012, TB-related deaths among people living with HIV 
declined by 36% worldwide[2]. However, TB continues to be the leading cause of death 
among people living with HIV, accounting for 25% of global HIV/AIDS-related deaths[1].
Antiretroviral therapy (ART) reduces the risk of active TB among people living with HIV[3, 
4]. But longitudinal studies that include data on TB incidence in both pre-ART to post-ART 
initiation periods are limited. In a large, prospective cohort of HIV-infected patients 
attending HIV care and treatment in Dar es Salaam, Tanzania, we estimated TB incidence 
rates by ART status and determined risk factors associated with TB incidence.
Methods
Study Population
We conducted a prospective observational cohort study of HIV-infected individuals enrolled 
in the Management and Development for Health (MDH)-supported HIV care and treatment 
clinics in Tanzania. With financial support from the Presidents’ Emergency Plan for AIDS 
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Relief (PEPFAR), the MDH Program was established in 2004 as a joint partnership between 
Muhimbili University of Health and Allied Sciences, Dar es Salaam City Council, and 
Harvard University. The MDH program provided infrastructure, laboratory and technical 
support to HIV care and treatment, integrated prevention of mother-to-child transmission of 
HIV, and TB services in the three municipalities of Dar es Salaam: Temeke, Ilala, and 
Kinondoni. From November 2004 to September 2012, 108,554 HIV-infected adults (≥15 
years of age) were enrolled in 50 MDH-supported HIV clinical sites. All patients received 
clinical care and treatment following national and WHO guidelines[5, 6].
We excluded patients who had previously taken ART (n=8,912), been diagnosed with TB or 
TB status was not recorded thereby missing within 30 days after enrollment (n=16,391), or 
did not have any follow-up visits (n=15,565). After these exclusions, our final sample size 
was 67,686 patients (Fig. 1). Among them, 53,056 (78%) were found eligible for and 
initiated ART during follow-up, the other 14,630 (22%) patients remained on care and 
monitoring services (ART naive).
The institutional review boards for human research at the Harvard School of Public Health 
and the ethics review committees at Muhimbili University of Health and Allied Sciences in 
Dar es Salaam approved the study.
ART Eligibility
Upon enrollment, each patient was assessed for eligibility for ART initiation. During the 
study period, ART initiation criteria for adults included the following: WHO stage IV, WHO 
stage III with CD4+ cell count <350 cells/uL, or CD4+ cell count <200 cells/uL. 
Antiretroviral drugs were provided free of charge by the Tanzanian government. Standard 
first-line ART regimens included 2 nucleoside reverse-transcriptase inhibitors (NRTI) 
[lamivudine (3TC) or emtricitabine (FTC), plus stavudine (d4T) or zidovudine (AZT) or 
Tenofovir (TDF)], and 1 nonnucleoside reverse-transcriptase inhibitor (NNRTI) [efavirenz 
(EFV) or nevirapine (NVP)]. To avoid drug interactions, EFV was substituted for NVP in 
patients receiving rifampin therapy for the treatment of TB. Patients who were not 
immediately eligible to initiate ART continued to receive routine care and monitoring 
service in the HIV clinics, and were started on ART once they met eligibility criteria[5, 6].
Participant Assessments
In general, clinic visits were scheduled at 2 weeks of ART, then monthly thereafter for 
patients on ART, and 3 to 6-montly for patients not receiving ART. Patients could come to 
clinics without an appointment during weekdays if necessary to seek extra care and 
treatment. At each clinic visit, patients were screened for TB based on clinical symptoms 
including cough, fever, night sweats, weight loss, and hemo rifampcin ptysis. Sputum 
smears and chest X-rays were administered to all TB suspected patients to assist with the 
diagnosis. Physicians and nurses completed standardized forms to capture demographic and 
clinical information. Nurses used standardized techniques to obtain anthropometric 
measurements, including height, weight, middle upper arm circumference (MUAC). Body 
mass index (BMI) was calculated as weight in kilograms divided by the square of the height 
in meters. Laboratory tests for CD4+ cell counts, hemoglobin and alanine aminotransferase 
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(ALT) concentrations were performed at enrollment, ART initiation, and every 6 months 
during follow-up. Viral load testing was not routinely performed.
Study variables
Incident TB cases were defined as patients who were free of TB at enrollment and newly 
diagnosed with TB by sputum smear or chest X ray, or prescribed anti-TB medications 
during follow-up. Demographic, clinical and nutritional characteristics were considered as 
independent variables, including age (<25, 25 to <35, 35 to <45, ≥45 years), sex (male/
female), district of residence (Ilala, Kinondoni, Temeke), BMI (<17, 17 to <18.5, 18.5 to 
<25, 25 to <30, ≥30 kg/m2), MUAC (<20, 20 to <22, 22 to <25, 25 to <27, ≥27 cm), 
Anemia (no, mild, moderate, severe), CD4+ cell counts (<50, 50 to <100, 100 to <200, ≥200 
cells/μL), WHO stage (I, II, III, IV), ALT (≤40, >40 U/L), pregnancy (no/yes), 
cotrimoxazole use (no/yes), Isoniazid preventive therapy (no/yes), ART (no/yes). ART 
regimens were grouped according to their NRTI (d4T, AZT or TDF) and NNRTI (EFV or 
NVP) agents. The use of INH has increased from 1.5% to 4.5% among patients over the 8 
years of study period, and 2,079 (3.1%) of the 67,689 patients in this study have received 
Isoniazid (INH) preventive therapy during the follow-up period. We grouped hemoglobin 
concentrations into the following categories according to World Health Organization 
(WHO) guidelines: severe anemia (hemoglobin, <8.0 g/dl), moderate anemia (8.0 to <11.0 
g/dl), mild anemia (11.0 to <13.0 g/dl for men and 11.0 to 12.0 g/dl for women), non-anemia 
(≥13.0 g/dl for men and ≥12.0 g/dl for women)[7]. Seasons of the clinical visit were 
categorized into long rainy (April-May), long dry (June-September), and short rainy 
(October-November), and Short dry (December-March). Nonadherence was defined as >5% 
noncompliance with scheduled visits.
Statistical analysis
Incidence rates were calculated by number of new incident TB diagnosed divided by person-
time followed up during no-ART and ART periods, respectively. Patients who have started 
ART during follow-up could contribute follow-up time to both non-ART and ART periods. 
Rates were presented per 100 person-years of follow-up, and 95% confidence intervals were 
calculated using exact Poisson probabilities. The primary outcome was time to first TB 
diagnosis after enrollment. The Andersen-Gill formulation of the Cox proportional hazard 
model was applied to evaluate the association between each baseline characteristic measured 
at enrolment and selected time-varying parameters with time to first TB event after 
enrollment[8]. Patients who did not experience incident TB were censored at death or loss to 
follow-up or the last visit date by September 30, 2012. Missing indicator variables were 
created for covariates with incomplete information. Multivariate models were fit including 
all variables that were associated with the primary outcome with P value less than 0.20 in 
the univariate analysis. Likelihood ratio tests were used to calculate the P values for nominal 
variables including district, season, and calendar months. The possibility of nonlinear 
relations between continuous covariates and the risk of incident TB was examined 
nonparametrically with restricted cubic splines[9]. All statistical tests were two-sided, with P 
less than 0.05 considered significant, and conducted using SAS 9.3 (Cary, North Caroline, 
USA).
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Results
At enrolment, the mean (±Standard Deviation, SD) age was 35.6(±9.7) years with 9% ≥50 
years; approximately 25% were male. The mean BMI was 22.3(±4.9) kg/m2, and 21% of the 
patients were underweight (defined by BMI<18.5 kg/m2). The mean CD4 was 268(±239) 
cells/uL, and 51% were WHO HIV stage III or IV. These and other characteristics at 
enrollment are presented in Table 1.
During the study period, 53,056 of 67,686 patients initiated ART, and the median time 
between enrollment and ART initiation was 31 (Inter Quartile Range (IQR), 16–158) days. 
During a median follow-up of 24 (IQR, 8–49) months, 7,602 of 67,686 patients developed 
incident TB. The incidence rate was 7.9 (95% CI, 7.6–8.2)/100 person-years for patients on 
care and monitoring (ART naïve), and 4.4 (95%CI, 4.2–4.4)/100 person-years for patients 
on ART.
Table 2 presents univariate and multivariate analyses for potential risk factors associated 
with incident TB. In multivariate analyses, male patients had a 53% significantly higher risk 
of developing TB than females [Hazard Ratio (HR), 1.53; 95%CI, 1.45–1.60]. Patients 
enrolled in the Kinondoni (HR, 1.22; 95%CI, 1.15–1.29) and Temeke (HR, 1.06; 95%CI, 
1.00–1.13) districts had a higher risk of developing TB than those enrolled in Ilala district. 
Patients enrolled in later calendar years tended to have a lower risk of TB than those 
enrolled in the earliest years of 2004–2005 when the HIV care and treatment program just 
started. Patients tended to have a relative higher risk of TB in the short rainy season 
(October–November). To further explore the seasonal pattern in TB risk, we examined the 
association of TB risk with calendar months, and found that higher risk TB was observed in 
months of May, June, and November, around the ends of the two rainy seasons in Dar es 
Salaam (Fig.2, P<0.001).
Time-varying nutritional status was significantly associated with TB risk. Compared with 
patients with normal BMI (18.5–<25.0kg/m2), patients with BMI<17.0 had a 2-fold 
increased risk of TB, while overweight and obese patients had 36% and 45% percent 
reduced risks, respectively (P value for trend<0.001). Similar associations were found 
between TB risk and MUAC (HR, 3.15; 95%CI, 2.86–3.46, comparing the lowest vs. 
highest categories; P value for trend <0.001). Patients with severe, moderate, and mild 
anemia a 103%, 66%, and 22% higher risks of TB, respectively, compared to those without 
anemia (P value for trend<0.001, Table 2).
Lower CD4+ cell counts and advanced WHO HIV disease stage were significantly 
associated with a higher risk of developing TB. Compared with patients with CD4+ ≥350 
cells/uL, those with CD4+<200 cells/uL had a significantly 5% to 20% higher risk of TB. 
Compared to patients who were WHO stage I, those who were WHO stage II, III, and IV 
had a 1.59, 3.54, and 3.44 times greater risk of TB, respectively (P for trend<0.001, Table 2)
After controlling for potential confounders, patients in the first 3 months of ART had a 57% 
higher risk of developing TB compared to patients who were not on ART. However, the risk 
of TB began to decrease with continued ART, patients who were on ART for 3–6, 6–12, 12–
24, 24–36, ≥36 months had a 21%, 27%, 47%, 59%, and 72% reduced risks of developing 
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TB compared to patients who were not on ART (Table 2). Among patients who have started 
ART in program, the relationship between risk of TB and duration on ART were further 
demonstrated in figure 3. From this graph we observed that the risk of TB increased over 
time before ART initiation, and reached highest level around ART initiation, after that the 
risk decreased over time with increasing months on ART (figure 3).
To compare the effect of different ART regimens on TB risk, a separate multivariate model 
was fit among patients who initiated ART during the follow-up period (n=53,056), 
Compared to patients receiving d4T-contaning regimens, those receiving AZT- or TDF-
containing regimens had 35% (HR:0.65, 95%CI: 0.60–0.70) and 10% (HR:0.90,95%CI:
0.77–1.05) reduced risks of incident TB, respectively; compared to patients receiving EFV-
containing regimens, those receiving NVP-containing regimens had a 64% (HR:
0.36,95%CI:0.34–0.39) reduced risk of incident TB (Table 2).
Discussion
In this large observational prospective cohort study of HIV-infected adults in Tanzania, we 
found that the incidence of TB was significantly lower for patients receiving ART than those 
who were not on ART. However, patients within the first three months following ART 
initiation had a temporary increased risk. Male gender, poor nutritional status, lower CD4 
cell count, and advanced HIV disease stage were associated with a higher risk of developing 
active TB. In addition, we found a seasonal fluctuation of TB incidence with higher risk in 
the end of rainy seasons in Dar es Salaam, Tanzania (May, June and November).
It is well documented that ART effectively reduces TB incidence among population in HIV 
endemic areas[3, 4, 10–12]. ART suppresses viral activity and promotes the restoration of 
the immune system, hence leading to a reduced risk of re-activating latent TB or of 
emerging opportunistic infections. However, TB incidence may rise during the initial 
months on ART, which is largely due to ART-induced unmasking of subclinical active TB 
and delayed diagnosed of unspecific symptomatic patients in resource-limited settings[13–
15]. The TB incidence pattern following ART initiation in the current study is consistent 
with findings from previous studies[16–20]. Data from South Africa[18, 20] and Nigeria[19] 
both demonstrated that TB incidence was higher in the first year of ART, then decreased 
over time thereafter. Similar to our previous finding among HIV-infected children, patients 
receiving NVP-containing ART regimens had a lower risk of developing of TB[21]. Due to 
the concerns over an advert drug interaction between NVP and rifampin (anti-TB therapy), 
EFV was recommend to replace NVP for TB-infected patients[5]. Therefore, the increased 
risk associated with EFV might be due to confounding by indication, meaning that patients 
who were suspected with TB infection but without enough evidence for diagnosis at ART 
initiation were more likely to be prescribed EFV-containing regimens.
Our study demonstrated that nutritional status is a strong predictor for TB risk among HIV-
infected adults. The bidirectional association between malnutrition and TB has been well 
documented in general population[22, 23]. However, there has been little evidence among 
HIV-infected populations receiving ART[24]. Several studies have indicated that poor 
nutritional status is associated with higher risks of mortality and opportunistic infection, 
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including TB, after ART initiation[25–27]. Furthermore, co-infection with HIV and TB 
exacerbates the malnutrition and wasting seen in TB or HIV infection alone, due to 
increased energy expenditure, decreased appetite, and nutrient malabsorption[28, 29]. To 
exclude the possibility of reverse causality, patients diagnosed with active TB within 30 
days after enrollment were excluded from the current analysis. To clarify the temporal 
relationship between nutritional status and incident TB, the time-varying nutritional status 
indicators, measured by BMI, MUAC and hemoglobin level, were associated with outcomes 
at least one month later in our analyses. To control the high TB risk and sustain the ART 
treatment outcomes, randomized controlled trials are warranted to confirm findings from 
observational studies and identify effective strategies to improve and maintain nutritional 
status among HIV-infected individuals.
In this study, we also found the risk of TB was higher at the end of rainy seasons (May, June 
and November). This may be due to people spending more time indoors during rainy 
seasons, thereby increasing close contact and exposure time to TB-infected individuals. The 
seasonal variation across the year might also be related to the seasonal fluctuation in vitamin 
D status. Several studies have suggested that vitamin D deficiency impairs the immune 
response to mycobacterial infection[30]. Evidence from observational studies has shown that 
vitamin D deficiency was associated with higher risk of TB in various populations[31–34]. 
In a previous study from Tanzania, Sudfeld and colleagues [35] found that the period of 
June through August was associated with the highest risk of low vitamin D status (25(OH)D 
<30 ng/mL) in HIV-infected adults. This finding is consistent with our result that the higher 
risk of TB was observed in the similar period from May to November. Randomized 
controlled trials of vitamin D supplementation for prevention of TB appear to be warranted 
for HIV-infected populations.
Consistent with published data, we identified several other risk factors for incident TB 
among HIV-infected population, including male, lower CD4+ cell counts[18, 36, 37], 
advanced HIV disease stage[18, 37]. We found that patients enrolled in Kinondoni and 
Temeke districts had a higher risk of TB compared those enrolled in Ilala. In Dar es Salaam, 
people living in Ilala district tend to have a higher social economic status, which might be 
associated with lower prevalence and incidence of TB infection among the population.
Our study had several strengths and limitations. First, the majority of the TB diagnoses were 
based on clinical syndromes. Physicians ordered sputum smear test and chest X-ray for all 
diagnosed TB patients in this study, but only 12% of them had a positive result on sputum 
smear and 7% positive on chest X-ray. Sputum cultures were not available in the HIV care 
and treatment clinics in Dar es Salaam. Because of the high TB incidence among the target 
population, sputum microbiologic confirmation was not required for the diagnosis and 
treatment of TB for patients attending the HIV clinics. Second, since viral loads were not 
routinely measured in the study population, and socio-economic data and other lifestyle 
factors including smoking, and diet, were not collected, we were not able to take them into 
account and potential residual confounding from these factors cannot be excluded. The 
strengths of the study include the large sample size and relatively long follow-up period. 
More than 75% of the patients started ART during the follow-up and contributed data and 
person-years in both pre-ART and post-ART periods, this allows us to calculate the TB 
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incidence by ART status, and examine the both short term and long term effects of ART on 
TB incidence.
In summary, our findings demonstrate that ART significantly reduced the incidence of 
active TB among HIV-infected individuals, despite a sharp increase in TB incidence during 
the initial months of ART due to unmasking of subclinical TB. Malnutrition, lower CD4 cell 
counts, and advanced WHO HIV disease state were significantly predictor of TB incidence, 
while seasonal variation played a role in the development of TB among HIV-infected 
population. A combined strategy targeting for improving and maintaining nutritional status, 
effective TB screening tools, timely initiation of ART, and controlling HIV disease 
progression is needed to reduce the high TB risk among HIV-infected population in 
resource-limited settings. In TB endemic regions, patients initiating ART, particularly males 
and those with poor nutritional status, should be closely monitored for active TB in the 
months following ART initiation. Further studies focused on nutritional interventions in the 
context of ART and HIV/TB co-infection are warranted.
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Fig. 1. 
Flow diagram for selection of study participants (MDH, Management and Development for 
Health; ART, antiretroviral therapy; TB, tuberculosis.)
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Fig. 2. 
Hazard Ratio of incident tuberculosis by calendar months among HIV-infected adults in Dar 
Salaam, Tanzania. Note: The diamonds show the Hazard Ratios with January as reference 
(HR=1.0); The vertical Bars show the 95% confidence intervals. (The P value was 
calculated based likelihood ratio test by running the multivariate Cox proportional hazard 
model twice, with and without the 11 calendar-month indicators included)
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Fig. 3. 
Hazard Ratio of incident tuberculosis by duration on ART (with zero as reference) among 
HIV-infected individuals in Dar es Salaam, Tanzania. Note: The horizontal dot line shows 
where the hazard ratio equal to 1; the solid line shows hazard ratio; the dot-dash lines show 
the 95% confidence intervals for hazard ratios; negative times represent time before ART 
initiation, only patients who have started ART during the follow-up were included to create 
the graph.
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Table 1
Patient Characteristics at Enrolment (n=67,686)
Variables n (%)
Age at enrollment (yrs),%
 <25 6,398(9.5)
 25–<35 27,609(40.8)
 35–<45 22,157(32.7)
 45+ 11,497(17.0)
Male sex, % 17,053(25.2)
Family size >3 members, % 8,615(14.6)
District of Dar es Salaam,%
 Ilala 26,784(39.6)
 Kinondoni 22,979(34.0)
 Temeke 17,803(26.4)
Year of enrolment,%
 2004 or 2005 3,658(5.4)
 2006 7,349(10.9)
 2007 10,279(15.2)
 2008 11,577(17.1)
 2009 11,068(16.3)
 2010 9,419(13.9)
 2011 8,101(2.0)
 2012 6,235(9.2)
Season of enrollment,%
 Dec.–Mar. (Short dry) 21,784(32.2%)
 Apr.–May (Long rainy) 10,835(16.0)
 Jun.–Sept. (Long dry) 23,895(35.3)
 Oct.–Nov. (Short rainy) 111,72(16.5)
BMI at enrollment (kg/m2),%
 <17 6,332(10.2)
 17–<18.5 6749(10.9)
 18.5–<25.0 33,784(54.7)
 25–<30.0 10,627(17.2)
 30.0+ 4,321(7.0)
MUAC at enrollment (cm),%
 <20 2,581(4.6)
 20–<22 5,137(9.1)
 22–<25 15,771(28.1)
 25–<27 12,061(21.4)
 27+ 20,671(36.8)
Anemia status,%
 Severe anemia 5,614(12.7)
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Variables n (%)
 Moderate anemia 19,796(44.8)
 Mild anemia 9,292(21.0)
 Non-anemia 9,467(21.4)
CD4+ cell counts at enrolment (cells/uL)
 <50 8,643(15.6)
 50–<100 6,346(11.4)
 100–<200 11,449(20.6)
 200–<350 13,297(23.9)
 350+ 15,836(28.5)
WHO Stage at enrollment,%
 I 17,627(26.6)
 II 14,941(22.6)
 III 25,138(38.0)
 IV 8,478(12.8)
ALT>40u/L at enrolment, % 4,832(11.3)
Cotrimoxazole use at enrollment, % 21,087(33.2)
ART regimensa
 D4T+3TC+NVP 13,816(37.7)
 AZT+3TC+NVP 5,965(16.3)
 TDF+FTC+NVP 32(0.1)
 D4T+3TC+EFV 2,489(6.8)
 AZT+3TC+EFV 13,351(36.5)
 TDF+FTC+EFV 940(2.6)
Values are means (standard deviation) unless specified;
Notes: BMI, body mass index; MUAC, middle upper arm circumference; ALT, alanine aminotransferase; ART, antiretroviral therapy.
a
Distribution of ART regimens among patients who started ART during the follow-up. (d4T, stavudine; AZT, zidovudine; TDF, tenofovir; EFV, 
efavirenz; NVP, nevirapine; 3TC, lamivudine; FTC, emtricitabine)
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Table 2
Risk factor for tuberculosis incidence among HIV-infected adults (n=67,686)
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Age (years, time-varying)
  <25 0.62(0.59–0.67) <0.001 0.77(0.69–0.87) 0.09
  25–<35 Ref. Ref.
  35–<45 1.17(1.11–1.23) 1.11(1.05–1.17)
  45+ 1.05(0.97–1.13) 0.99(0.92–1.05)
Male 1.90(1.81–1.99) <0.001 1.53(1.45–1.60) <0.001
Pregnant womena 0.18(0.15–0.23) <0.001 0.43(0.34–0.53) <0.001
District
  Ilala Ref. <0.001 Ref. 0.02
  Kinondoni 1.12(1.07–1.19) 1.22(1.15–1.29)
  Temeke 1.14(1.07–1.20) 1.06(1.00–1.13)
Family size (members)
  ≤3 Ref. <0.001 Ref. 0.74
  >3 0.91(0.85–0.98) 0.99(0.92–1.06)
Year of enrollment
  2004 or 2005 Ref. <0.001 Ref. <0.001
  2006 0.97(0.88–1.07) 0.98(0.89–1.08)
  2007 0.91(0.83–1.00) 0.94(0.86–1.03)
  2008 0.78(0.71–0.85) 0.80(0.73–0.88)
  2009 0.74(0.67–0.82) 0.76(0.69–0.85)
  2010 0.68(0.62–0.76) 0.74(0.67–0.83)
  2011 0.66(0.59–0.74) 0.85(0.75–0.97)
  2012 0.71(0.62–0.81) 1.12(0.88–1.44)
Season of visit (time-varying)
  Dec.–Mar. (Short dry) Ref. <0.001 Ref. 0.13
  Apr.–May (Long rainy) 1.06(0.99–1.14) 0.99(0.93–1.06)
  Jun.–Sept. (Long dry) 1.13(1.07–1.20) 1.00(0.95–1.06)
  Oct.–Nov. (Short rainy) 1.11(1.04–1.19) 1.06(0.98–1.13)
BMI (kg/m2,time-varing)b
  <17.0 3.07(2.88–3.27) <0.001 1.96(1.83–2.09) <0.001
  17.0–<18.5 2.25(2.11–2.40) 1.69(1.58–1.80)
  18.5–<25.0 Ref. Ref.
  25.0–<30.0 0.48(0.44–0.52) 0.64(0.59–0.70)
  30+ 0.36(0.31–0.41) 0.55(0.48–0.62)
MUAC (cm, time-varying)b
  <20.0 5.99(5.48–6.54) <0.001 3.15(2.86–3.46) <0.001
  20.0–<22.0 4.53(4.19–4.90) 2.68(2.47–2.91)
  22.0–<25.0 2.48(2.33–2.64) 1.81(1.69–1.93)
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Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
  25.0–<27.0 1.59(1.48–1.71) 1.35(1.25–1.45)
  27.0+ Ref. Ref.
Anemia status (time-varying)
  Severe anemia 3.57(3.28–3.89) <0.001 2.03(1.86–2.22) <0.001
  Moderate anemia 2.08(1.93–2.23) 1.66(1.55–1.79)
  Mild anemia 1.47(1.35–1.59) 1.22(1.13–1.33)
  No anemia Ref. Ref.
CD4+ cell counts (cells/uL, time-varying)
  <50 3.36(3.02–3.74) <0.001 1.04(0.92–1.17) <0.001
  50–<100 3.17(2.84–3.54) 1.18(1.04–1.33)
  100–<200 2.51(2.26–2.78) 1.20(1.07–1.35)
  200–<350 1.15(1.04–1.27) 0.81(0.72–0.91)
  350+ Ref. Ref.
WHO HIV disease stage (time-varying)
  I Ref. <0.001 Ref. <0.001
  II 2.13(1.91–2.37) 1.59(1.42–1.78)
  III 5.96(5.41–6.56) 3.54(3.20–3.92)
  IV 7.62(6.85–8.48) 3.44(3.06–3.87)
ALT (u/L, time-varying)
  ≤40 Ref. <0.001 Ref. 0.78
  >40 1.33(1.24–1.43) 1.01(0.94–1.08)
Cotrimoxazole (time-varying)
  No Ref. <0.001 Ref. 0.11
  Yes 1.28(1.20–1.36) 1.05(0.99–1.12)
Isoniazid preventive therapy (time-varying)
  No Ref. <0.001 Ref. <0.001
  Yes 2.29(1.58–3.32) 2.25(1.55–3.27)
Nonadherence (time-varying)
  No Ref. <0.92
  Yes 1.00(0.94–1.07)
Months on ART (time-varying)
  None Ref. <0.001 Ref. <0.001
  >0 and <3 3.34(3.15–3.54) 1.57(1.47–1.68)
  3–<6 1.67(1.51–1.85) 0.79(0.71–0.88)
  6–<12 1.48(1.34–1.65) 0.73(0.65–0.81)
  12–<24 1.16(1.04–1.29) 0.54(0.48–0.60)
  24–<36 0.91(0.79–1.04) 0.41(0.36–0.48)
  36+ 0.69(0.59–0.80) 0.28(0.25–0.33)
ART agentsc
 NRTI
  d4T Ref. <0.001 Ref. <0.001
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Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
  AZT 0.87(0.82–0.91) 0.65(0.60–0.70)
  TDF 1.69(1.48–1.94) 0.90(0.77–1.05)
 NNRTI
  EFV Ref. <0.001 Ref. <0.001
  NVP 0.49(0.47–0.52) 0.36(0.34–0.39)
Notes: HR, Hazard Ratio; CI, confidence interval; BMI, body mass index; MUAC, middle upper arm circumference; ALT, alanine 
aminotransferase; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase 
inhibitor; d4T, stavudine; AZT, zidovudine; TDF, tenofovir; EFV, efavirenz; NVP, nevirapine;
a
The comparison was conducted among women only, the reference group is non-pregnant women.
b
In multivariate analysis, BMI and MUAC were included into separate models. And the model with BMI was used get HR and 95%CI for other 
variables.
cOnly patients who started ART during the follow-up period were included into the analysis to examine the association of ART agents with TB 
risk.
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